Index

Page numbers in italics denote figures, those in bold denote tables.

A
abdominal binders 255
abortion, spontaneous 164, 166
acanthosis nigricans 191, 244, 244
acarbose, with insulin 126
access to care 8
ACCORD study 10, 31, 85, 113, 203, 205, 215, 218, 222, 263
ACE inhibitors 192, 193, 204, 211, 221
acetaminophen 231
Action to Control Cardiovascular Risks in Diabetes see ACCORD study
adherence to treatment antihypertensive therapy 193
gestational diabetes 163
Specific DecisionPath 72–3, 72
type 1 diabetes 72–3, 72
type 2 diabetes 132–3
adhesive capsulitis 245
adjust phase 10, 14, 27
adolescents see children and adolescents
ADOPT study 82
ADVANCE study 85–6, 203
advanced glycosylation end-products 230
Afrezza 74
African Americans
gestational diabetes 140, 141
insulin resistance 166
type 1 diabetes 44, 45
type 2 diabetes 11, 87, 88, 89, 90, 177
Alaska Natives
gestational diabetes 140, 141
type 2 diabetes 11, 87, 88, 89, 90, 177
aldo reductase inhibitors 231
alignment 1–3
ALLHAT study 210, 211, 221
α-glucosidase inhibitors 82
with insulin 126
selection of 102
side-effects 101, 103
Alzheimer disease 256
ambulatory glucose profile 32, 33
gestational diabetes 154, 166
glucose exposure 24, 33, 37
glucose stability 24, 34–5, 35
glucose variability 24, 33, 34
normal 47
pregnancy 140, 148
type 1 diabetes 49, 50
American Association of Clinical Endocrinologists 12
American Association of Diabetes Educators 12
American Diabetes Association 8, 12, 30, 45, 81
amlodipine 210, 211
dosage 214
amyotrophy 230
angiotensin receptor blockers 192, 193, 194, 221
anti-GAD antibodies 44, 45, 46
antidiabetes therapy 198
antibiotics, with GLP-1 agonists 110
anticoagulants, with GLP-1 agonists 110
antioxidant therapy 216
Appropriate Blood Pressure Control in Diabetes Trial 222
Asian Americans
gestational diabetes 140, 141
insulin resistance 166
thrifty genes 78
type 1 diabetes 45
type 2 diabetes 11, 87, 88, 89, 90, 177
asparg 48, 52, 115
aspirin 216, 231
athletes foot 244
atorvastatin
dosage 214
LDL-lowering effects 214
autoantibodies 44
azotemia 217
B
basal energy expenditure 96
bed-wetting 45
behavioral issues 58
gestational diabetes 162–3
type 1 diabetes 72–4
type 2 diabetes 132–6, 132
β-blockers 192
β-cells
destruction of 43, 44
dysfunction 77–9
exhaustion 166
bevacizumab 228
biguanides 31, 81–2
bile acid sequestrants 196, 197, 221, 231
dosage 214
LDL-lowering effects 215
Bland–Altman analysis 32
blood glucose see glucose
blood pressure measurement 206–7
self-monitored 193, 206, 221
target 210
see also hypertension
BMI 51
assessment 69, 93–5, 95
children and adolescents 168, 169, 170, 175
goals 183
see also obesity
body fat distribution 79
body mass index see BMI
bonuses 3
boys, BMI 169
Brazil, SDM in 28
bulimia 253
diagnosis 254
C
C-peptide 45
type 2 diabetes 90
C-reactive protein 204
calcium channel blockers 192, 211
calorie requirements 96
CAMELOT study 211
cancer 259
Candida albicans 246
candidiasis 243–6, 245
capsaicin 231
carbohydrate counting
children and adolescents 181, 182
type 2 diabetes 97, 97, 130
cardiovascular disease 203–16
dyslipidemia/hyperlipidemia see dyslipidemia/hyperlipidemia
hypertension see hypertension
INDEX

cardiovascular disease (cont’d)

274
INDEX
gestational diabetes (cont’d)
insulin therapy 147–8, 158–61, 158–60
basal/bolus insulin 159–61, 160
insulin analogues 158
mixed insulin 158–9, 158, 159
patient education 158
Master DecisionPath 149–61, 150
MNT 147, 152–5, 152–4, 156
adjust phase 155
maintain phase 155
start phase 152–5, 152–4
monitoring 149
obesity 153–4
patient education 151–2
practice guidelines 145–9, 146
prevention 142–3
record-keeping 154
screening 145–6, 146, 147
treatment targets 147–9, 148
selection of regimen 151
see also pregnancy
girls, BMI 169
glucose 48, 53–4, 115, 158
and malignancy 112
glucagon 264
glucagon-like peptide 1 receptor agonists 9, 83–4
GLP-1 agonists 9, 82, 151
GLP-1 82, 151
glomerular filtration rate 220
GLP-1 82, 151
GLP-1 agonists 9, 83–4, 83, 106–11
with antibiotics, oral contraceptives, analgesics, and antiplatelet agents 110
exenatide as monotherapy 106–7
exenatide with thiazolidinedione 106, 110
initiating therapy 107–10, 108, 109
with insulin 110, 126
liraglutide with thiazolidinedione and metformin 106
with metformin and/or sulfonylurea 106, 109, 110
patient education 110–11
side-effects and contraindications 107

glucagon 264

glucagon-like peptide 1 receptor agonists see GLP-1 agonists

glucose 11
ambulatory profile see ambulatory glucose profile
diurnal profiles 29, 32–8, 32, 33–5, 86, 86
fasting 45, 80
and HbA1c 29, 48
mean 30
monitoring see glucose monitoring
postmeal rises 50
in pregnancy 139–45
random 151
see also hyperglycemia; hypoglycemia

glucose exposure 24, 33, 37

glucose homeostasis 29–39
impaired 33–6, 37
see also prediabetes
normal 35–8, 37, 37, 38

glucose monitoring 98
children and adolescents 177, 178, 181–2, 182
continuous see CGM
gestational diabetes 153, 157

self-monitoring see SMBG
type 1 diabetes 49–50, 50
CGM 57–8
HbA1c 37–8
SMBG 37–8
type 2 diabetes
CGM 108
SMBG 24, 44, 98, 108
usually impaired patients 228
glucose stability 24, 34–5, 35
glucose tolerance 36
impaired 80–1
normal 86
glucose toxicity 64, 80, 85, 166

glucose transporter 4 81

GLP-1 agonists

hyperglycaemic
glucose monitoring; hyperglycemia; hypoglycaemia

glucose-dependent insulinotropic peptide 79

glutamic acid decarboxylase, autoantibodies see anti-GAD antibodies
glucose analogue 82, 101
contraindications 156

glomerular filtration rate 220

H

Harris–Benedict equation 96

Hawaiian Natives
gestational diabetes 140, 141
type 2 diabetes 11, 87, 88, 89, 90, 177
HbA1c 1, 8, 23
and blood glucose 29, 48
children and adolescents 173, 176, 182, 182
in clinical decision-making 25
elevation with normal glucose 38
frequency of measurement 25
gestational diabetes 153
in glycemic control 23–4, 24
screening 45–6
target level 10, 24
type 1 diabetes 24, 57–8
type 2 diabetes 24, 90
when not to use 25

height assessment 69

herpesvirus, and type 1 diabetes 44

high-density lipoproteins 196, 205, 215

hirsutism 197, 251

Hispanics
gestational diabetes 140, 141
insulin resistance 166
type 2 diabetes 88, 89, 90
HLA-DR2 44
HLA-DR3 43
HLA-DR4 43
honeymoon period 52, 56, 64

hormone replacement therapy 216

hospitalization 261–2

diabetic ketoacidosis 265–7, 266
discharge 269
effect of 262
glycemic control 262
poor 264, 265, 266
hyperglycaemia 261–2
prevention 262–3
hyperglycaemic hyperosmolar syndrome 267
hypoglycaemia 263–5, 264
MNT 269
practitioners guidelines 273
surgery 267–9, 268, 269, 270

human leukocyte antigen see HLA

hyperglycaemia 29, 45, 80
children and adolescents 173
corticosteroid-induced 261–2
detection 206
hospital setting 261–2
insulin initiation during 125
management 206, 212, 277
metabolic syndrome 191
and nephropathy 218
and neuropathy 230
postmeal 102
in pregnancy 67, 141–2
prevention 262–3
and retinopathy 221–2
severe 127
three-component program 262–3
hyperglycaemic hyperosmolar syndrome 125, 127, 188
hospitalisation 267
insulin infusion protocol 268
hyperinsulinaemia 45, 78, 85
children and adolescents 186–7
type 2 diabetes, insulin therapy 112
hyperlipidaemia see dyslipidaemia/hyperlipidaemia
hypertension 205
children and adolescents 191–3, 192
classification 192
detection 206
diagnosis 23, 192, 206
etiology 205
follow-up 192
lifestyle modifications 109, 201
management 192, 194, 221
adjust phase 193, 211
start phase 192–3, 207–11, 208–10

Master DecisionPath 208
metabolic syndrome 191
monitoring 192
and nephropathy 218
practice guidelines 207
and retinopathy 222
risk factors 191–2
screening 191–2

276
INDEX

symptoms 207
targets 192
white coat 206
hypoglycemia 29, 36
children and adolescents 186–7
and concurrent illness 67
DecisionPath 264
hospitalization 263–5, 264
investigation 264–5
management 66–7, 127–8
prevention 128
symptoms 128
type 2 diabetes 85
insulin therapy 111–12
I
ibuprofen 231
illness see comorbidities; sick days
incentives 3
combination therapy 84–5
incretin dysfunction 79–80
incretin effect 80
incretin dysfunction 79–80
incretins 9, 31, 151
incentives 3
insulin resistance syndrome
insulin/insulin therapy 9, 10
insulin resistance 10, 36, 78, 79, 92, 93, 98, 102
insulin receptor substrates 79
insulin resistance syndrome see metabolic syndrome
insulin secretagogues 9, 82, 156
combination therapy 84
meglitinides 82
sulfonylureas see sulfonylureas
see also individual drugs
insulin sensitizers 9, 81–2
biguanides 31, 81–2
combination therapy 84
thiazolidinediones 31, 81
see also individual drugs
insulin-to-carbohydrate ratio 55, 124, 130, 190
insulin/insulin therapy 9, 10
action curves 52, 126
adjustment guidelines 27
aspart 48, 52, 115
basal/bolus 48, 54–5, 54, 55
children and adolescents 188–9
correction factor 55, 56
gestational diabetes 159–61, 160
type 1 diabetes 54
type 2 diabetes 85, 118–20, 118, 119, 119
children and adolescents 178
basal/bolus 188–9
mixed 200
multidose 186–90
conventional 48
cost-effectiveness 113–14
delivery methods 74, 116–17
needle-free techniques 74
pens and needles 74
pumps see insulin pumps
detemir 48, 53–4, 115, 158
with DPP-4 inhibitors 105, 126
gestational diabetes see under gestational diabetes
glargin 48, 53–4, 115, 158
and malignancy 112
with GLP-1 agonists 110, 126
glulisine 48, 115, 158
infusion protocol 268
inhaled 74
intermediate-acting 47, 53, 115
children and adolescents 187–8
lispro 47–8, 52, 115, 158
long-acting 47, 115
children and adolescents 187–8
low-dose, in diabetes prevention 44
maximum safe dose 14
with metformin 185–6
mixed
children and adolescents 200
gestational diabetes 158–9, 158, 159
type 1 diabetes 56–64, 58–61
multidose 186–90
one-injection regime 64
patient education 67–72, 116, 131
premixed 85, 115, 120–1, 130, 131
rapid-acting 47, 115
children and adolescents 187–8
relative insulin deficiency 78
short-acting 47, 53, 115
with sitagliptin 105
three-injection regimes 61–2, 62, 63
type 1 diabetes see under type 1 diabetes
type 2 diabetes see under type 2 diabetes
ultra-long-acting 74
ultra-rapid-acting 74
visually impaired persons 228
and weight gain 113
with metformin 185–6
insulins 44
integrated care model 1–4, 2
case for 1
measurement of change 3–4
theoretical principles 1–3
interleukin-6 204
International Diabetes Center 8, 28
International Diabetes Federation 12, 30
International Federation of Clinical Chemistry and Laboratory Medicine 30
interquartile range 33
interviews 20
intrauterine growth retardation 162
islets of Langerhans, lymphocyte infiltration 44
J
joint mobility, limited 244–5
JUPITER study 204
K
ketoconazole 245
ketones 26, 45
children and adolescents 174–5
in concurrent illness 67
measurement 50
monitoring 25
type 1 diabetes 50
type 2 diabetes 89
urinary 11
knowledge of diabetes 21
Kumamoto Study 111
Kussmaul breathing 65
L
laboratory data, review of 19
lactic acidosis 267
laser photocoagulation therapy 227
latent autoimmune diabetes of adults 45
LDL see low-density lipoproteins
leadership 3
learning 3
learning organizations 3
lifestyle modifications
dyslipidemia/hyperlipidemia 212–14
hypertension 109, 201
linagliptin 105
Linjeta 74
lipid-lowering agents 214–15, 214, 215
adjust/maintain phase 214–15, 215
lipohypertrophy 244
lipotoxicity 78
liraglutide 84, 106
injection 107
patient education 111
side-effects 107
starting dose 109
with thiazolidinediones 106
lisinopril 210, 211
lispro 47–8, 52, 115, 158
lopenamide 231
lovastatin
dosage 214
LDL-lowering effects 214
low-density lipoproteins 196, 205, 215
drugs reducing 214
low-protein diet 221
lower extremity amputation 238
M
macronutrients
type 1 diabetes 69–70, 70
type 2 diabetes 96–7
macrosomia 162, 168
macular edema 227–8
maintain phase 10
Master DecisionPaths 1, 9, 10, 12–13, 12, 13, 22
children and adolescents
type 2 diabetes 191–200, 191
weight management 171, 172–5
customization of 26
dyslipidemia 213
foot care 238
gestational diabetes 149–61, 150
hypertension 208
type 1 diabetes 12, 45, 51–2, 51
type 2 diabetes 13, 81, 82, 92–127
Patient Health Questionnaire-2 256
Patient Health Questionnaire-9 257
patient participation 14
pay-for-performance 3
PCOS see polycystic ovary syndrome
pegaptanib 228
periodontal disease 245
peripheral neuropathy 231
peroxisome proliferator-activated receptors see PPARs
phosphotyrosine residues 79
physical assessment 70
pioglitazone
policy alignment 1–2
Pittsburgh Epidemiology of Diabetes Comlications Study 204
plantar ulcers
complex 243–4
simple 241–3, 241–3
policy alignment 1–2
polycystic ovary syndrome 93, 184, 191, 197–8, 251–3, 252, 253
diagnosis 197, 252
follow-up 252
management 197–8, 251, 252, 253,
253
monitoring and follow-up 197
practice guidelines 252
risk factors 197, 252
screening 197, 251, 252
symptoms 197, 252
polydipsia 23, 45
diabetic ketoacidosis 65
polyphagia 23, 45
diabetic ketoacidosis 65
polyuria 23, 45
diabetic ketoacidosis 65
Portland Diabetic Project 262
PPAR-γ 81
PPARs 81
practice guidelines 10–12, 11, 22–6
adoption of 22
children and adolescents 174–8, 175
customization of 22–6
diagnosis 23
dyslipidemia 219
follow-up and surveillance 25–6
foot care 237–8, 237
genital diabetes 145–9, 146
hospitalization 273–7
hypertension 219
monitoring 24–5, 24
neuropathy 218
neuropathy 229, 230
polycystic ovary syndrome 252
retinopathy 223, 224
screening 22–3, 87–91, 145–6
sharing of 26–7
treating to target 23–4, 24
treatment 23, 91–2
type 1 diabetes 46
type 2 diabetes 11, 87–92, 88–90, 91
pramlintide 64
adjust phase 66
start phase 65
pravastatin
dosage 214
LDL-lowering effects 214
prayer sign 244–5
prediabetes 80–1, 90–1, 91
children and adolescents 166
DecisionPaths 91
Prediction and Prevention Project 44
preeclampsia 152, 154
pregabalin 231
pregestational diabetes 161–2, 161
treatment options 162
pregnancy 139–64
ambulatory glucose profile 140, 148
behavioral issues 162–3
diabetes guidelines 141
epidemiology of diabetes 139–40
fetal and maternal assessment 162
glucose abnormalities 140–1
glucose control 144–5, 144, 145
hyperglycemia 67, 141–2
intrauterine growth retardation 162
normal ambulatory glucose profile 140
preconception planning 143–4
preeclampsia 152, 154
pregestational diabetes 161–2, 161
preterm labor 152
type 1 diabetes 67, 68, 143–4
type 2 diabetes 143
see also gestational diabetes
premixed insulin 85, 120–1, 130, 131
adjust phase 120–1, 121
start phase 120, 120
preterm labor 152
primary care provider 15–16
process specificity 2
protein kinase C-β 222
proteinuria 217
catalytic assessment
gestational diabetes 163
one type 1 diabetes 73–4
type 2 diabetes 133–4
psychologists 16
psychosocial assessment 198–9
R
diabetic retinopathy 230
ramipril 221
random plasma glucose 151
ranibizumab 228
reactive oxygen species 79
Reaven syndrome see metabolic syndrome
record-keeping
CMM 70
exercise/activity 70, 154
food plans 70, 154
gestational diabetes 154
SMBG 70
rehydration therapy in diabetic ketoacidosis 65
reimbursement 3
relative insulin deficiency 78
diabetic ketoacidosis 65
replacement therapy 45
renal disease see nephropathy
repepaglinide, selection of 102
replace, reduce, restrict approach 96, 130
children and adolescents 180–1
report cards 3
report writing 20
resource alignment 1–2
retinopathy 80, 221–8
cataracts 223
diagnosis 223–4
and dyslipidemia 222
glaucoma 223
and hyperglycemia 221–2
and hypertension 222
management 224, 227–8
macular edema 227–8
nonproliferative retinopathy 224, 227
proliferative retinopathy 228
nonproliferative 226
management 224, 227
practice guidelines 223, 224
proliferative 222, 226
management 228
screening 223–4
stages of 222–3, 223
symptoms 225, 226
risk factors 11
rosiglitazone 82, 103
and metformin 94
safety 81–2
rosuvastatin 204
dosage 214
LDL-lowering effects 214
rubella virus, and type 1 diabetes 44
russia, SDM in 28
ruvastatin 214
S
San Antonio Heart Study 203
saxagliptin 84, 105
with thiazolidinediones 105
schizophrenia 256, 258
scientiﬁc evidence, reproducibility of 8
scleroderma 244
scleroderma-like syndrome 244
screening 11, 22–3
children and adolescents 90, 90, 174–6, 177
weight management 168
depression 256, 257
dyslipidemia 196
eating disorders 253–4, 253
foot complications 234–9, 235–9
genital diabetes 145–6, 146, 147
HbA1c 45–6
hypertension 191–2
microalbuminuria 195–6
nephropathy 193–4, 194, 210, 219–20
neuropathy 228–9
polycystic ovary syndrome 197, 251, 252
practice guidelines 22–3, 87–91, 145–6
retinopathy 223–4
type 1 diabetes 45
type 2 diabetes 87–91, 88
Screening and Diagnosis DecisionPath 45
SDM see Staged Diabetes Management
SEARCH for Diabetes in Youth study 165
self-monitored blood glucose see SMBG
self-monitored blood pressure 193, 206, 221
Semmes–Weinstein monofilament test 235, 236
serum creatinine 101
sharing the vision 22
shin spots 244
INDEX

sick days 67
food plans 127
management of 127
therapy changes 269
simvastatin
dosage 214
LDL-lowering effects 214
sitagliptin 84, 103
and insulin 105
and metformin 94
side-effects 105
sleep disorders 198, 258
SMBG 11, 14, 30, 49–50
children and adolescents 177, 178, 182
frequency of measurement 24, 24, 25
gestational diabetes 149, 153
in glycemic control 23–4, 24
interpretation 31
patient education 130–1, 131, 131
record-keeping 70
representation 31
timing 31, 125
type 1 diabetes 24, 57–8
type 2 diabetes 24, 44, 98, 108
underreporting 30
verifiability 30
visually impaired patients 228
snacks, weight management 173, 174
social assessment 73–4
social workers 16
somatostatin 221
Specific DecisionPaths 10, 13–14, 13
review of 27
treatment adherence 72–3, 72
type 2 diabetes 13
Staged Diabetes Management 1–4, 7–16
customization of 21–8
definition 20–1
development of 7–8
foundational principles 8
implementation 17–28
Master DecisionPaths see Master
DecisionPaths
patient participation 14
phases of 10
practice guidelines 10–12, 11
purpose of 1
Specific DecisionPaths 13–14, 13
stages 8–10, 9
stakeholders 20
start phase 10, 27
statins 196, 204, 221
dosage 214
LDL-lowering effects 214
Strong Heart Study 203
sulfonylureas 9, 82, 83
allergy to 101
with GLP-1 agonists 106
maximum safe dose 14
with metformin 104–5
selection of 102
and weight gain 156
see also individual drugs
surgery 267–9, 268, 269, 270
emergency 268, 269
planned 267–9, 268
postoperative care 269
surveillance 25–6
symptoms 11
syndrome X see metabolic syndrome
T
team development 16
Technosphere 74
TEDDY study 44
telsartan 221
tetracycline 231
therapy changes 14
food plans 97, 181
sick days 214, 269
thiazolidinediones 31, 81, 83, 101
with DPP-4 inhibitors 104–5
with exenatide 106
with iraglutide 106
safety 81–2
selection of 102
side-effects 103
see also individual drugs
three-component program 262–3
thirty genes 78
thromboxane 216
throughputs 20
time lag 31, 50
tinea pedis (athlete’s foot) 244
treating to target 23–4, 24, 36
type 2 diabetes 85–6
Treating to Target in Type 2 Diabetes study
group 113
treatment
co-managing 26
guidelines 23
initial therapy 26
options 11
review 19, 26
targets 11, 23–4, 24
see also individual conditions
treatment choice 26
treatment targets
gestational diabetes 148–9, 148
type 1 diabetes 48
type 2 diabetes 88
TrialNet 44
TRIGR study 44
truncal mononeuropathy 230
tumor necrosis factor-α 79
twin studies 43–4
type 1 diabetes 43–75
adults
diagnosis 45
treatment targets 48
ambulatory glucose profile 49, 50
behavioral issues 72–4
adherence 72–3, 72
disagreement 73
psychological and social assessment 73–4
children and adolescents 45
diagnosis 45
growth and development 51
treatment targets 48
complications 51, 64–7
diabetic ketoacidosis 65–6
hypoglycemia 66–7
diagnosis 23, 44–6
diagnostic criteria 45
differential diagnosis 46
etiology 43–4
exercise/activity 72
follow-up 51
food plan 67–72, 70
glucose monitoring 49–50, 50
CGM 57–8
HbA1c 57–8
SMBG 57–8
glycemic targets 24
HLA typing 43–4
honeymoon period 52, 56, 64
immune markers 45
insulin pump 48, 56, 57
insulin therapy 52–64, 52
basal/bolus 54
intermediate-acting 53
long-acting analogues 53–4
mixed 56–61, 58–61
mixed three injections 62–4, 63
one injection 64
rapid-acting analogues 52
short-acting 53
three-injection regimes 61–2, 62, 63
management 46–64, 50
adjustment and maintenance 64
co-management 55–6
targets 48–9, 48
Master DecisionPath 12, 45, 51–2, 51
MNT 45, 52
patient education 67–72
physiological state 44
practice guidelines 46
pramlintide 64
preconception planning 68
pregestational 161–2, 161
pregnancy 67, 68, 143–4
prevention 74
risk prediction 74
screening 45
HbA1c 45–6
twin studies 43–4
type 2 diabetes 77–137, 78
additional therapies 104–6
behavioral issues 132–6, 132
adherence assessment 132–3
psychological and social assessment 133–4
children and adolescents 165–200
etiology 166, 166
major studies 167
Master DecisionPath 191–200, 191
prevention 166–7
risk factors 165–6
treatment options 167
co-management 126–7
comorbidities 191–8
complications 21, 88, 92, 127–8, 178
concurrent illness 127
hypoglycemia 127–8
severe hyperglycemia 127
detection 87
diagnosis 23, 88–91, 88–90
HbA1c 90
ketones 89
differential diagnosis 46
doctor–patient relationship 97–8
documentation 99
DPP-4 inhibitors
  with insulin 105
  with metformin and/or sulfonylureas 104–5
side-effects and contraindications 105–6
  with thiazolidinediones 105
ethnic predisposition 78, 87
etiology 77–81
  β-cell dysfunction 77–8
  impaired glucose tolerance 80–1
  incretin dysfunction 79–80
  insulin resistance 79
  prediabetes 80–1
exercise/activity 98, 100, 101
follow-up 88, 92, 99–100
interventions 100
food plan 94, 96–7
GLP-1 agonists 106–11
  exenatide as monotherapy 106–7
  exenatide with thiazolidinedione 106
  liraglutide with thiazolidinedione and metformin 106
  with metformin and/or sulfonylurea 106
side-effects and contraindications 107
  glucose monitoring
  CGM 108
  SMBG 24, 44, 98, 108
  glycemic targets 24
insulin levels and C-peptide 90
insulin resistance see insulin resistance
insulin therapy 84–5, 111–27
  adjustment 125, 125, 127
  back to baseline 126
  basal/bolus regimen 85, 121–4, 122–4
  choice of 117–25, 117–24, 119
  cost-effectiveness 113–14
  delivery devices 116–17
  with DPP-4 inhibitors 126
  effectiveness of 112–13
  with GLP-1 agonists 126
  with α-glucosidase inhibitors 126
  initiation 115–17, 116, 125
  with metformin 126
  with oral agents 85
patient preparation 116
  premixed 85, 120–1, 130, 131
safety 111–12
  titration 119
  under acute hyperglycemia 125
  weight gain 113
Master DecisionPaths 13, 81, 82, 92–127
medical emergencies 89
MNT 81–5, 82, 83, 84, 91–2, 93–100
  adjust phase 98–100, 99
  maintain phase 100
  start phase 93–8, 94, 95, 96, 97
  monitoring 88, 92
  and nephropathy 218–19
oral agents
  choice of 101, 102
  combination 104–6
  contraindications 101
  failure of 105–6
  monotherapy 100–4
  patient education 128–32
  exercise/activity 131–2
  GLP-1 agonists 110–11
  MNT 129–30, 130
  SMBG 130–1, 131, 131
practice guidelines 11, 87–92, 88–90, 91
  pregestational 161–2, 161
  pregnancy 128, 143
  prevention 86–7
  progress evaluation 98, 99
  risk factors 89
  screening 87–91
  children and adolescents 90, 90
  self-management skill review 99
  short-term goals 99
  Specific DecisionPaths 13
  symptoms 89
  treatment 81–7
    combination therapy 83–4, 83, 84
    guidelines 91–2
    MNT 81–5, 82, 83, 84, 91–2
    treat to target 86–7, 87
  treatment targets 88
U
UK Prospective Diabetes Study (UKPDS) 10, 31, 45, 111, 203
urinary ketones 11
utilization data 18
V
values
  alignment 1–2
  fit 3
vegetables, in weight management 175
Veterans Affairs Cooperative Study 111
Veterans Affairs Diabetes Trial 203
vildagliptin 105
vitamin B6 216
vitamin B12 216
vitamin C 216
vitamin E 216
vitreous hemorrhage 226
W
waist-to-hip ratio 79
weight gain 71
  children and adolescents 186–7
  and insulin therapy 113
  metabolic syndrome 191
see also obesity
weight management
  adjustments 99
  assessment 69
  children and adolescents 167–72, 168, 173–5
  diagnosis 168
  follow-up 171
  Master DecisionPath 171, 172–5
  monitoring 171
  risk factors 168
  screening 168
  targets 168, 171
  treatment options 168
white coat hypertension 206
Wisconsin Epidemiologic Study of Diabetic Retinopathy 222
Women’s Health Study 204
working group 20
World Health Organization 12
X
xanthoma diabeticorum 244
xerostomia 245–6
Y
Yellow Springs Instruments analyzer 31